Availability: In StockBiological Description:KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells. Selectivity profiling with recombinant tyrosine kinases showed that KRN633 is highly selective for VEGFR-1, -2, and -3. KRN633 inhibits tumor growth in several in vivo tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN633 also causes the regression of some well-established tumors and those that had regrown after the cessation of treatment. KRN633 was well tolerated and had no significant effects on body weight or the general health of the animals. KRN633 might be useful in the treatment of solid tumors and other diseases that depend on pathologic angiogenesis.Purity: >98.00%Molecular formula: C₂₀H₂₁ClN₄O₄ Molecular Weight: 446.90Storage Instructions: Two years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSOReferences: for more information, please visit images/AffixScientific/

Affix Scientific633克朗

CAS号：286370-15-8

成为第一个评论该产品

包装 *

尺寸

 1克$ 1650

价格：            $ 1650.00

数量：

1

库存：有存货

目录号 286370-15-8

生物学描述：

KRN633是一种有效的选择性VEGFR抑制剂。抑制人脐静脉内皮细胞中VEGFR-2的酪氨酸磷酸化（IC50 = 1.16 nmol / L）。用重组酪氨酸激酶进行的选择性分析表明，KRN633对VEGFR-1，-2和-3具有高度选择性。在无胸腺小鼠和大鼠中，KRN633在几种具有不同组织起源的体内肿瘤异种移植模型（包括肺，结肠和前列腺）中抑制肿瘤生长。KRN633还可以使一些公认的肿瘤以及那些在停止治疗后已长出的肿瘤消退。KRN633具有良好的耐受性，对动物的体重或总体健康没有明显影响。KRN633可用于治疗实体瘤和其他依赖病理性血管生成的疾病。

纯度： > 98.00％

分子式： C 2 0 H 2 1 ClN 4 O 4  

分子量： 446.90

储存说明：两年-20°C粉末，2周DMSO中4°C，DMSO中6个月-80°C